Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI

  1. Vallejo-Vaz, A.J.
  2. Bray, S.
  3. Villa, G.
  4. Brandts, J.
  5. Kiru, G.
  6. Murphy, J.
  7. Banach, M.
  8. De Servi, S.
  9. Gaita, D.
  10. Gouni-Berthold, I.
  11. Kees Hovingh, G.
  12. Jozwiak, J.J.
  13. Jukema, J.W.
  14. Gabor Kiss, R.
  15. Kownator, S.
  16. Iversen, H.K.
  17. Maher, V.
  18. Masana, L.
  19. Parkhomenko, A.
  20. Peeters, A.
  21. Clifford, P.
  22. Raslova, K.
  23. Siostrzonek, P.
  24. Romeo, S.
  25. Tousoulis, D.
  26. Vlachopoulos, C.
  27. Vrablik, M.
  28. Catapano, A.L.
  29. Poulter, N.R.
  30. Ray, K.K.
  31. Show all authors +
Journal:
Cardiovascular Drugs and Therapy

ISSN: 1573-7241 0920-3206

Year of publication: 2023

Volume: 37

Issue: 5

Pages: 941-953

Type: Article

DOI: 10.1007/S10557-022-07343-X GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals